Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-03-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - RNV 8 pages 20.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from RENERVE LIMITED regarding the application for quotation of newly issued securities on the ASX. It details the number and type of securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document references previous announcements (Appendix 3B) related to the securities issuance. This type of document is a formal application to list or quote securities on a stock exchange, which corresponds to announcements about share issues or capital changes. It is not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not a mere announcement of a report but a substantive filing about capital changes.
2025-03-13 English
Cleansing Notice 2 pages 183.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 14 March 2025, notifying the market under section 708A(5)(e) of the Corporations Act 2001 (Cth) about the issue of 666,212 fully paid ordinary shares by ReNerve Limited. The notice confirms compliance with relevant sections of the Act and states that the shares were issued without disclosure under Part 6D.2. The content is a formal regulatory announcement about a share issue event, not a full financial report or detailed capital raising document. The document length is short (2540 characters) and it is a direct notice of a capital transaction. This fits the category of Share Issue/Capital Change announcements rather than a full Capital/Financing Update report or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-03-13 English
Proposed issue of securities - RNV 5 pages 17.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed placement or other type of securities issue by RENERVE LIMITED. It includes specifics such as the number of securities to be issued, the issue date, and compliance with ASX Listing Rules. The content focuses on the announcement of a new securities issue rather than financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or capital changes. The document length and detail confirm it is not a brief notice or a report publication announcement but a full announcement of a capital change event.
2025-03-12 English
Marketing Approval in Thailand & Initial Sales in Hong Kong 2 pages 271.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 11 March 2025 from ReNerve Limited regarding marketing approval of a medical product (NervAlign® Nerve Cuff) in Thailand and initial sales in Hong Kong. It contains no financial statements, no detailed financial data, no regulatory certifications, or voting results. It is a business update about product marketing approval and initial sales, which fits the category of a Capital/Financing Update or general company operational update. However, since it is specifically about marketing approval and initial sales rather than fundraising or capital structure changes, it is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other categories. The document length is 4051 characters, which is short and typical for an announcement rather than a full report. Therefore, the best classification is Regulatory Filings (RNS).
2025-03-10 English
ReNerve Receives Additional $139K R&D Refund 1 page
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 7 March 2025 regarding ReNerve Limited receiving an additional R&D tax incentive refund. It discusses the amount of the refund, the company's product development, and upcoming clinical study presentations. There are no financial statements, detailed financial results, or comprehensive report content. The document is relatively short (2775 characters) and serves as an update on a specific financial event (tax refund) and company progress rather than a full financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is an announcement about a financing-related event (receipt of tax refund), which aligns best with Capital/Financing Update (CAP).
2025-03-06 English
1HFY25 Appendix 4D and Half Year Report 23 pages 552.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ReNerve Limited Appendix 4D Half-year report' and covers the half-year ended 31 December 2024. It includes detailed financial statements such as the statement of profit or loss, statement of financial position, and notes to the financial statements. The presence of comprehensive financial data and analysis for a half-year period indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is substantial and contains actual financial statements, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-02-27 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.